Alterations of striatal dopamine D2 receptors contribute to deteriorated response to l-dopa in Parkinson's disease: A [123I]-IBZM SPET study

G. Pizzolato, F. Chierichetti, A. Rossato, A. Cagnin, M. Fabbri, M. Dam, G. Ferlin, L. Battistin

Research output: Contribution to journalArticle

Abstract

Single photon emission tomography with the ligand [123I]-IBZM was used to image central dopamine D2 receptors in Parkinson's disease patients. The aim was to assess striatal receptor densities in relation to response to L-Dopa therapy. In the parkinsonian patients group who were untreated until SPET study and in the group of patients with a sustained response to chronic L-Dopa, striatal [123I]-IBZM uptake did not differ significantly from mean values of the control group. On the contrary, significantly diminished uptake of [123I]-IBZM was found in the basal ganglia regions of the group of patients who developed a complicated/fluctuating response to chronic L-Dopa treatment. Our results indicate that striatal D2 receptor alterations in Parkinson's disease may contribute to the altered response to L-Dopa.

Original languageEnglish
Pages (from-to)113-122
Number of pages10
JournalJournal of Neural Transmission, Supplement
Issue number45
Publication statusPublished - 1995

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Alterations of striatal dopamine D2 receptors contribute to deteriorated response to l-dopa in Parkinson's disease: A [123I]-IBZM SPET study'. Together they form a unique fingerprint.

  • Cite this

    Pizzolato, G., Chierichetti, F., Rossato, A., Cagnin, A., Fabbri, M., Dam, M., Ferlin, G., & Battistin, L. (1995). Alterations of striatal dopamine D2 receptors contribute to deteriorated response to l-dopa in Parkinson's disease: A [123I]-IBZM SPET study. Journal of Neural Transmission, Supplement, (45), 113-122.